D
LSL Pharma Group Inc. LSL.V
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
EPS (TTM)

06/30/2025 03/31/2025 12/31/2024 09/30/2024 06/30/2024
Revenue 59.26% 62.72% 74.23% 77.07% 57.17%
Total Other Revenue -- -- -- -- --
Total Revenue 59.26% 62.72% 74.23% 77.07% 57.17%
Cost of Revenue 46.33% 40.66% 45.69% 37.56% 19.43%
Gross Profit 103.41% 152.03% 219.08% 1,132.14% 2,089.53%
SG&A Expenses 31.86% 44.08% -12.26% -10.84% -23.72%
Depreciation & Amortization 4.84% 4.84% 4.84% -297.15% --
Other Operating Expenses -- -- -- -- --
Total Operating Expenses 42.46% 40.84% 21.21% 14.79% -0.69%
Operating Income 191.46% 132.55% 108.09% 87.33% 83.79%
Income Before Tax 219.63% 196.73% 138.00% 76.16% 74.28%
Income Tax Expenses -- -- -- -- --
Earnings from Continuing Operations 217.92% 195.29% 137.43% 76.16% 74.28%
Earnings from Discontinued Operations -- -- -- -- --
Extraordinary Item & Accounting Change -- -- -- -- --
Minority Interest in Earnings -- -- -- -- --
Net Income 217.92% 195.29% 137.43% 76.16% 74.28%
EBIT 191.46% 132.55% 108.09% 87.33% 83.79%
EBITDA 14,037.67% 468.32% 150.40% 108.02% 100.36%
EPS Basic 187.24% 166.45% 122.58% 80.90% 78.81%
Normalized Basic EPS 64.47% 66.31% 81.11% 71.18% 70.88%
EPS Diluted 167.72% 152.77% 119.37% 77.58% 75.15%
Normalized Diluted EPS 64.47% 66.31% 81.11% 71.18% 70.88%
Average Basic Shares Outstanding 30.08% 36.29% 32.79% 26.40% 22.89%
Average Diluted Shares Outstanding 30.10% 36.39% 32.89% 26.50% 22.93%
Dividend Per Share -- -- -- -- --
Payout Ratio -- -- -- -- --